Mark A. Kryah has been leading projects ranging from early to late phase development for over 16 years, with extensive international, cross-cultural and partnership experience. He has led numerous product registrations, and consistently demonstrated an ability to build strong cross-functional working relationships, to effectively and confidently manage operational complexity, and to deliver strong business results.
Mr. Kryah joined Eli Lilly in June 1986 as Project Engineer in Plant/Process Engineering. He had subsequent assignments in Human Resources, Quality Assurance, and Pharmaceutical Manufacturing prior to joining Lilly’s Generics Business Unit as Project Leader in December 1995. After taking financial and manufacturing strategy responsibilities for the Infectious Diseases Business Unit, Kryah joined the Prozac Product Team as Pharmaceutical Project Manager in January 1998, leading submissions and approvals for various line extensions and new indications.
In May 2001, he moved to CMC Project Management, where he managed CMC development for multiple projects, including Effient (prasugrel) global registration and approval, Prozac for Japan and multiple co-development partnerships in Europe and Japan.
Kryah was named COO, Urology Platform Team, in October 2010, where he was responsible for global development of assets ranging from Ph3 thru post-launch (Ph4). In September 2013, he moved to a COO role in Lilly's Autoimmune Platform, leading development and preparation for registration of a Ph3 asset. In June 2014, Kryah was promoted to Sr. Advisor/COO of Lilly's late phase Cardiovascular Platform.
Kryah obtained Project Management Professional (PMP) certification from the Project Management Institute (PMI) in April 1999 and currently maintains that designation.
Specialties: Project and program management, global product development and registrations, CMC, Ph3/4 development, alliances/co-development partners, Japan.